Header Logo

Connection

THOMAS WHEELER to Prostatectomy

Back to Details
This is a "connection" page, showing publications THOMAS WHEELER has written about Prostatectomy.
THOMAS WHEELER
Connection Strength
4.022
Prostatectomy
  1. Editorial Comment. J Urol. 2017 12; 198(6):1323.
    View in: PubMed
    Score: 0.489
  2. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun; 37(6):726-34.
    View in: PubMed
    Score: 0.224
  3. Radical prostatectomy for carcinoma of the prostate. Mod Pathol. 2004 Mar; 17(3):349-59.
    View in: PubMed
    Score: 0.192
  4. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 07 13; 377(2):132-142.
    View in: PubMed
    Score: 0.121
  5. Fresh tissue harvest for research from prostatectomy specimens. Prostate. 1994 Nov; 25(5):274-9.
    View in: PubMed
    Score: 0.100
  6. Metabolomic signatures of aggressive prostate cancer. Prostate. 2013 Oct; 73(14):1547-60.
    View in: PubMed
    Score: 0.091
  7. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting. Histopathology. 2013 Jan; 62(2):203-18.
    View in: PubMed
    Score: 0.088
  8. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int. 2011 Oct; 108(7):1074-85.
    View in: PubMed
    Score: 0.078
  9. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol. 2011 Jan; 24(1):6-15.
    View in: PubMed
    Score: 0.075
  10. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011 Jan; 24(1):16-25.
    View in: PubMed
    Score: 0.075
  11. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol. 2011 Jan; 24(1):39-47.
    View in: PubMed
    Score: 0.075
  12. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011 Jan; 24(1):26-38.
    View in: PubMed
    Score: 0.075
  13. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011 Jan; 24(1):48-57.
    View in: PubMed
    Score: 0.075
  14. A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis. BJU Int. 2011 Feb; 107(3):389-95.
    View in: PubMed
    Score: 0.075
  15. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology. 2009 Apr; 251(1):122-33.
    View in: PubMed
    Score: 0.068
  16. Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol. 2008 Oct; 32(10):1503-12.
    View in: PubMed
    Score: 0.066
  17. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology. 2007 Nov; 70(5):965-9.
    View in: PubMed
    Score: 0.062
  18. Significance of the craniocaudal distribution of cancer in radical prostatectomy specimens. Int J Urol. 2007 Sep; 14(9):817-21.
    View in: PubMed
    Score: 0.061
  19. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol. 2006 Sep; 176(3):991-5.
    View in: PubMed
    Score: 0.057
  20. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005 May; (216):34-63.
    View in: PubMed
    Score: 0.052
  21. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol. 2004 Jul; 28(7):928-34.
    View in: PubMed
    Score: 0.049
  22. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004 May 01; 22(9):1655-63.
    View in: PubMed
    Score: 0.048
  23. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol. 2004 Jan; 171(1):204-9.
    View in: PubMed
    Score: 0.047
  24. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003 Dec; 170(6 Pt 1):2292-5.
    View in: PubMed
    Score: 0.047
  25. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J. 2003 Nov-Dec; 9(6):454-60.
    View in: PubMed
    Score: 0.047
  26. Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible? J Urol. 2003 Mar; 169(3):964-8.
    View in: PubMed
    Score: 0.045
  27. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol. 2002 Nov; 168(5):2011-5.
    View in: PubMed
    Score: 0.044
  28. Low-grade prostate cancer should still be labelled cancer. BJU Int. 2022 12; 130(6):741-743.
    View in: PubMed
    Score: 0.043
  29. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002 Feb; 167(2 Pt 1):528-34.
    View in: PubMed
    Score: 0.041
  30. Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol. 2001 Nov; 25(11):1429-32.
    View in: PubMed
    Score: 0.041
  31. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol. 2001 Aug; 32(8):828-33.
    View in: PubMed
    Score: 0.040
  32. Bilateral nerve graft during radical retropubic prostatectomy: 1-year followup. J Urol. 2001 Jun; 165(6 Pt 1):1950-6.
    View in: PubMed
    Score: 0.040
  33. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001 Jun 01; 19(11):2856-64.
    View in: PubMed
    Score: 0.040
  34. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000 Dec; 164(6):1929-34.
    View in: PubMed
    Score: 0.038
  35. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol. 2000 Jun; 24(6):859-63.
    View in: PubMed
    Score: 0.037
  36. Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. Am J Surg Pathol. 1999 Aug; 23(8):932-6.
    View in: PubMed
    Score: 0.035
  37. Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Arch. 2019 Sep; 475(3):263-277.
    View in: PubMed
    Score: 0.034
  38. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999 May; 17(5):1499-507.
    View in: PubMed
    Score: 0.034
  39. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol. 1999 Jan; 161(1):188-92.
    View in: PubMed
    Score: 0.033
  40. Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology. 2019 Jan; 51(1):11-20.
    View in: PubMed
    Score: 0.033
  41. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998 Aug; 29(8):856-62.
    View in: PubMed
    Score: 0.033
  42. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998 May 20; 90(10):766-71.
    View in: PubMed
    Score: 0.032
  43. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998 Jan 01; 82(1):168-75.
    View in: PubMed
    Score: 0.031
  44. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997 Jul; 50(1):93-9.
    View in: PubMed
    Score: 0.030
  45. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol. 1997 Jun; 157(6):2212-8.
    View in: PubMed
    Score: 0.030
  46. The striated urethral sphincter: muscle fibre types and distribution in the prostatic capsule. Br J Urol. 1997 Apr; 79(4):539-42.
    View in: PubMed
    Score: 0.030
  47. Staging and reporting of prostate cancer--sampling of the radical prostatectomy specimen. Cancer. 1996 Jul 15; 78(2):366-8.
    View in: PubMed
    Score: 0.028
  48. Impalpable prostate cancer: clinicopathological features. Br J Urol. 1996 Mar; 77(3):429-32.
    View in: PubMed
    Score: 0.028
  49. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer. 1995 Dec 15; 76(12):2530-4.
    View in: PubMed
    Score: 0.027
  50. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995 Nov; 154(5):1818-24.
    View in: PubMed
    Score: 0.027
  51. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995 Jan; 153(1):104-10.
    View in: PubMed
    Score: 0.025
  52. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov; 152(5 Pt 2):1843-9.
    View in: PubMed
    Score: 0.025
  53. Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer. Br J Urol. 1994 Jul; 74(1):72-9.
    View in: PubMed
    Score: 0.025
  54. Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol. 2014 Jul; 45(7):1365-9.
    View in: PubMed
    Score: 0.024
  55. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol. 1993 Dec; 17(12):1252-61.
    View in: PubMed
    Score: 0.024
  56. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun; 189(6):2039-46.
    View in: PubMed
    Score: 0.022
  57. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn. 2013 Mar; 15(2):270-9.
    View in: PubMed
    Score: 0.022
  58. Do adenocarcinomas of the prostate with Gleason score (GS) =6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012 Sep; 36(9):1346-52.
    View in: PubMed
    Score: 0.022
  59. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol. 1992 Aug; 148(2 Pt 1):331-7.
    View in: PubMed
    Score: 0.021
  60. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
    View in: PubMed
    Score: 0.020
  61. Transrectal ultrasonography in stage A prostate cancer: detection of residual tumor after transurethral resection of prostate. J Urol. 1991 Aug; 146(2):366-71.
    View in: PubMed
    Score: 0.020
  62. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol. 2011 Jul; 136(1):98-107.
    View in: PubMed
    Score: 0.020
  63. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87.
    View in: PubMed
    Score: 0.019
  64. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010 Jul; 184(1):149-56.
    View in: PubMed
    Score: 0.018
  65. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Clin Cancer Res. 2009 May 15; 15(10):3568-73.
    View in: PubMed
    Score: 0.017
  66. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.017
  67. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol. 1988 Sep; 140(3):544-9.
    View in: PubMed
    Score: 0.016
  68. Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features. J Urol. 2008 May; 179(5):1762-7; discussion 1767.
    View in: PubMed
    Score: 0.016
  69. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology. 2008 Jun; 71(6):1166-71.
    View in: PubMed
    Score: 0.016
  70. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
    View in: PubMed
    Score: 0.015
  71. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20.
    View in: PubMed
    Score: 0.015
  72. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007 Feb 01; 25(4):349-55.
    View in: PubMed
    Score: 0.015
  73. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.014
  74. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
    View in: PubMed
    Score: 0.014
  75. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005 Mar 15; 103(6):1186-94.
    View in: PubMed
    Score: 0.013
  76. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol. 2004 Aug; 172(2):508-11.
    View in: PubMed
    Score: 0.012
  77. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
    View in: PubMed
    Score: 0.012
  78. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004 Jun; 63(6):1191-7.
    View in: PubMed
    Score: 0.012
  79. Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res. 2004 Mar 15; 64(6):2076-82.
    View in: PubMed
    Score: 0.012
  80. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate. 2004 Feb 01; 58(2):193-9.
    View in: PubMed
    Score: 0.012
  81. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol. 2004 Jan; 171(1):200-3.
    View in: PubMed
    Score: 0.012
  82. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003 Oct 01; 63(19):6244-51.
    View in: PubMed
    Score: 0.012
  83. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res. 2003 Sep 15; 63(18):5874-8.
    View in: PubMed
    Score: 0.012
  84. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003 Oct 01; 21(19):3573-9.
    View in: PubMed
    Score: 0.012
  85. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res. 2003 Jul-Aug; 23(4):3413-8.
    View in: PubMed
    Score: 0.011
  86. IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):184-91.
    View in: PubMed
    Score: 0.011
  87. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002 Oct 15; 62(20):5974-9.
    View in: PubMed
    Score: 0.011
  88. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? J Clin Oncol. 2002 Apr 15; 20(8):2025-30.
    View in: PubMed
    Score: 0.011
  89. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002 Feb 01; 20(3):833-41.
    View in: PubMed
    Score: 0.010
  90. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001 Dec; 58(6):1008-15.
    View in: PubMed
    Score: 0.010
  91. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001 Feb 15; 19(4):1030-9.
    View in: PubMed
    Score: 0.010
  92. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology. 2000 Sep 01; 56(3):423-9.
    View in: PubMed
    Score: 0.009
  93. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70.
    View in: PubMed
    Score: 0.009
  94. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer. 1996 Sep 15; 78(6):1267-71.
    View in: PubMed
    Score: 0.007
  95. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994 Nov; 152(5 Pt 2):1714-20.
    View in: PubMed
    Score: 0.006
  96. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology. 1994 Jan; 43(1):60-6; discussion 66-7.
    View in: PubMed
    Score: 0.006
  97. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol. 1991 Nov; 68(5):499-509.
    View in: PubMed
    Score: 0.005
  98. The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol. 1991 Feb; 145(2):324-8; discussion 328-9.
    View in: PubMed
    Score: 0.005
  99. Staging of prostate cancer. Value of ultrasonography. Urol Clin North Am. 1989 Nov; 16(4):713-34.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.